CRDL Cardiol Therapeutics

EQS-News: Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

EQS-News: Cardiol Therapeutics
Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

16.12.2022 / 18:26 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive Canada

Proactive Canada


News Source: News Direct

16.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Cardiol Therapeutics
United States
ISIN: CA14161Y2006
EQS News ID: 1515789

 
End of News EQS News Service

1515789  16.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1515789&application_name=news&site_id=research_pool
EN
16/12/2022

Underlying

CRDLCardiol Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cardiol Therapeutics

 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics Reports Results of 2024 Annual General and Specia...

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024....

June 27, 2024 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics to Webcast Virtual Annual General and Special Mee...

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General and Special Meeting of Shareholders (the "AGM") will be webcast on June 26, 2024, at 4:30 p.m. EDT. Cardiol Therapeutics 2024 AGMWhen: June 26, 2024, at 4:30 p.m. EDTWhere: Virtual meeting only via live audio webcast online at: Additional...

June 25, 2024 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics Announces Positive Topline Data from its Phase II...

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyToronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported 8-week clinical data from...

June 13, 2024 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the ...

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart FailureARCHER trial has now exceeded 85% of target patient enrollment MAvERIC-Pilot Phase II study investigating CardiolRx™ for recurrent pericarditis expected to report topline results in early June 2024Toronto, Ontario--(Newsfile Corp. - May 14, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardi...

May 14, 2024 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditisExceeded 50% enrollment in the Phase II ARCHER trial evaluating CardiolRx™in patients with acute myocarditis; study expected to reach full enrollment during Q3 2024Data presented at the HFSA Annual Scientific Sessions 2023 demonstrated that the API in Cardiol's novelCRD-38 formulation attenuates harmful fat d...

April 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch